Application Note

Capture Of Bispecific Antibodies And Removal Of Product-Related Impurities

Source: Cytiva

The biotherapeutics pipeline is becoming increasingly diverse as antibody variants move through preclinical stages to commercial manufacturing. Many of these variants, especially asymmetric bispecific antibodies, are prone to aggregation or to forming product-related impurities such as homodimers and half antibodies during cell culture. The similarities between these impurities present extra challenges for downstream processes. One potential solution is to initiate polishing at the capture step using differences in avidity. Explore the application of a resin with novel selectivity to purify challenging entities.

access the Application Note!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.

Subscribe to Drug Discovery Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Drug Discovery Online